bit.bio

bit.bio, a synthetic biology company, was spun out of the University of Cambridge in 2016 by Dr. Mark Kotter. Originally named Elpis Biomed, the company rebranded to bit.bio to reflect its focus on the intersection of coding and biology. The founder, Dr. Kotter, is a neurosurgeon and stem cell biologist whose research at Cambridge University led to the development of the company's core technology. His motivation stems from a desire to transition biology into an engineering discipline to address significant patient needs, a path he embarked on after deciding at nineteen to pursue medicine to make a difference in people's lives. The company has secured substantial funding, raising approximately $225 million from investors including Arch Venture Partners, Blueyard Capital, Foresite Capital, and Tencent.

The company's core business revolves around its proprietary cell coding platform, which facilitates the creation of consistent, scalable batches of any human cell type. This is achieved through a patented gene-targeting approach called opti-ox™ (optimised inducible overexpression). This technology reprograms human induced pluripotent stem cells (iPSCs) into specific, mature cell types by controlling the expression of key transcription factors. By overcoming the inconsistencies and scalability issues of traditional stem cell differentiation, bit.bio provides a reliable source of human cells for research, drug discovery, and the development of cell therapies. The business generates revenue by selling its cell products and through strategic partnerships with pharmaceutical and research organizations.

bit.bio's primary product line is marketed under the brand ioCells. This portfolio includes a variety of human cell types, such as nerve, immune, and muscle cells, available as wild-type cells, disease models, and CRISPR-ready cells for gene editing applications. These products offer researchers and drug developers access to physiologically relevant human cell models, aiming to bridge the 'translation gap' that often leads to high failure rates in clinical trials. The company's discovery platform utilizes genetic screening and machine learning to identify the precise transcription factor combinations required to create any desired cell type. Through collaborations with entities like BlueRock Therapeutics and Charles River Laboratories, bit.bio is expanding the application of its technology towards creating a new generation of medicines and cell therapies accessible to every patient.

Keywords: cell programming, synthetic biology, iPSC, induced pluripotent stem cells, opti-ox, cell therapy, drug discovery, human cells, cellular reprogramming, regenerative medicine, stem cell manufacturing, ioCells, transcription factors, genetic engineering, biomedical research, preclinical models, disease modeling, functional genomics, high-throughput screening, neurodegenerative disease research